A single dose of lonvoguran ziclumeran (lonvo-z) left more than 60% of patients with hereditary angioedema (HAE) free of swelling attacks and ongoing therapy during a six-month evaluation period, suggesting it could reduce the need for lifelong preventive therapy if approved. That is according to topline data from…